Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study

J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J. P. Hallé, I. Hramiak, P. Johnston, M. Davis

Research output: Contribution to journalLetterpeer-review

129 Scopus citations
Original languageEnglish
Pages (from-to)1971-1973
Number of pages3
Issue number9
StatePublished - Sep 2009


  • Cancer
  • Insulin analogues
  • Insulin glargine
  • Insulin therapy
  • Malignancy
  • NPH insulin
  • Type 2 diabetes

Cite this